DK0988301T3 - Imidazolylcykliske acetaler - Google Patents

Imidazolylcykliske acetaler

Info

Publication number
DK0988301T3
DK0988301T3 DK98929548T DK98929548T DK0988301T3 DK 0988301 T3 DK0988301 T3 DK 0988301T3 DK 98929548 T DK98929548 T DK 98929548T DK 98929548 T DK98929548 T DK 98929548T DK 0988301 T3 DK0988301 T3 DK 0988301T3
Authority
DK
Denmark
Prior art keywords
imidazolylcyclic
acetals
tnf
inhibitors
compounds
Prior art date
Application number
DK98929548T
Other languages
Danish (da)
English (en)
Inventor
Paul Lindsay Bamborough
Alan John Collis
Frank Halley
Richard Alan Lewis
David John Lythgoe
Jeffrey Mark Mckenna
Iain Mcfarlane Mclay
Barry Porter
Andrew James Ratcliffe
Paul Andrew Wallace
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712270.9A external-priority patent/GB9712270D0/en
Priority claimed from GBGB9724678.9A external-priority patent/GB9724678D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DK0988301T3 publication Critical patent/DK0988301T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
DK98929548T 1997-06-12 1998-06-12 Imidazolylcykliske acetaler DK0988301T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9712270.9A GB9712270D0 (en) 1997-06-12 1997-06-12 Chemical compounds
US5218597P 1997-07-10 1997-07-10
GBGB9724678.9A GB9724678D0 (en) 1997-11-21 1997-11-21 Chemical compounds
US8549998P 1998-05-14 1998-05-14

Publications (1)

Publication Number Publication Date
DK0988301T3 true DK0988301T3 (da) 2006-11-13

Family

ID=27451664

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98929548T DK0988301T3 (da) 1997-06-12 1998-06-12 Imidazolylcykliske acetaler

Country Status (26)

Country Link
US (2) US6602877B1 (fr)
EP (1) EP0988301B1 (fr)
JP (1) JP4380803B2 (fr)
KR (1) KR100704059B1 (fr)
CN (1) CN100443481C (fr)
AT (1) ATE335735T1 (fr)
AU (1) AU742293B2 (fr)
BR (1) BR9810007B1 (fr)
CA (1) CA2293436C (fr)
CY (1) CY1105238T1 (fr)
CZ (1) CZ9904452A3 (fr)
DE (1) DE69835518T2 (fr)
DK (1) DK0988301T3 (fr)
ES (1) ES2270520T3 (fr)
HK (1) HK1032586A1 (fr)
HU (1) HUP0003309A3 (fr)
IL (2) IL133311A0 (fr)
NO (1) NO326660B1 (fr)
NZ (1) NZ501714A (fr)
PL (1) PL199893B1 (fr)
PT (1) PT988301E (fr)
RU (1) RU2221795C2 (fr)
SK (2) SK286940B6 (fr)
TR (1) TR199903098T2 (fr)
TW (1) TWI235751B (fr)
WO (1) WO1998056788A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
EP1112070B1 (fr) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
ATE336484T1 (de) 1998-08-29 2006-09-15 Astrazeneca Ab Pyrimidine verbindungen
ES2274634T3 (es) 1998-08-29 2007-05-16 Astrazeneca Ab Compuestos de pirimidina.
WO2000035911A1 (fr) * 1998-12-16 2000-06-22 Aventis Pharma Limited Acetals heteroaryl-cycliques
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
US6291457B1 (en) * 1999-07-01 2001-09-18 Merck & Co., Inc. Compounds having cytokine inhibitory activity
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
BR0015532A (pt) 1999-11-22 2002-06-25 Smithkline Beecham Plc Compostos
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
WO2003022837A1 (fr) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Derives heterocycles de carboxamide utilises comme inhibiteurs de raf kinase
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (fr) 2002-03-09 2003-09-18 Astrazeneca Ab Derives de la pyrimidine substituee par 4-imidazolyle presentant une activite d'inhibition de cdk
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1534282B1 (fr) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions pharmaceutiques comprenant des agents anticholinergiques etinhibiteurs de p38 kinase pour le traitement des maladies respiratoires
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TWI317286B (en) 2003-12-31 2009-11-21 Targeting delivery system
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AR056556A1 (es) 2005-09-30 2007-10-10 Astrazeneca Ab Imidazo(1,2-a)piridina con actividad antiproliferacion celular
JP2009512724A (ja) * 2005-10-24 2009-03-26 エフ．ホフマン−ラ ロシュ アーゲー Ｆａｖｏｒｓｋｉｉ転位による環状ケタール化ケトンの製造およびグルコキナーゼ活性化剤：７０を製造するためのその使用
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
PT2432767E (pt) * 2009-05-19 2013-07-25 Dow Agrosciences Llc Compostos e métodos para controlo de fungos
CN111356687B (zh) * 2019-03-27 2021-03-30 广州必贝特医药技术有限公司 含嘧啶的三取代咪唑类化合物及其应用
MX2022011143A (es) 2020-03-11 2022-10-13 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4175127A (en) 1978-09-27 1979-11-20 Smithkline Corporation Pyridyl substituted 2,3-dihydroimidazo[2,1-b]thiazoles
WO1983002613A1 (fr) 1981-07-20 1983-08-04 Sallmann, Alfred Composes oxazoiques a triple substitution
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US4728656A (en) 1985-12-12 1988-03-01 Smithkline Beckman Corporation 2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
EP0264883A3 (fr) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Dérivés de la pyridine substitués
ATE60776T1 (de) 1986-11-21 1991-02-15 Ciba Geigy Ag Ungesaettigte phosphonsaeure und derivate.
US4837350A (en) 1986-12-15 1989-06-06 Ciba-Geigy Corporation Process for the preparation of benzoin sulfonates
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
AU6307690A (en) * 1989-09-27 1991-04-11 Rhone-Poulenc Sante Imidazoles
GB9020889D0 (en) * 1990-09-25 1990-11-07 May & Baker Ltd New compositions of matter
US5102848A (en) 1990-09-28 1992-04-07 Union Carbide Chemicals & Plastics Technology Corporation Catalyst composition for oxidation of ethylene to ethylene oxide
GB9106508D0 (en) * 1991-03-27 1991-05-15 Rhone Poulenc Rorer Ltd New compositions of matter
US5179117A (en) 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
EP0624159B1 (fr) * 1992-01-13 1998-11-25 Smithkline Beecham Corporation Imidazoles a substitution par pyridyle
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
WO1995003297A1 (fr) 1993-07-21 1995-02-02 Smithkline Beecham Corporation Imidazoles actives contre les maladies transmises par la cytokine
JPH0753546A (ja) 1993-08-09 1995-02-28 Kuraray Co Ltd ジアリール置換複素環化合物およびその医薬用途
JPH09505055A (ja) 1993-11-08 1997-05-20 スミスクライン・ビーチャム・コーポレイション サイトカイン媒介疾患治療用オキサゾール
DE69401486T2 (de) 1993-11-12 1997-04-30 Ishihara Sangyo Kaisha Verfahren zur Herstellung 2-cyanoimidazol Derivate
EP0793653A1 (fr) 1994-11-23 1997-09-10 Neurogen Corporation Certains derives 4-aminomethyl 2-substitues de l'imidazole et derives 2-aminomethyl 4-substitues de l'imidazole, nouvelles categories de ligands specifiques du sous-type du recepteur de la dopamine
DE69627006T2 (de) 1995-08-10 2004-01-15 Merck & Co Inc 2-substituierte aryl-pyrrolen, zusammensetzungen solche verbindungen enthaltend und deren verwendung
EP0871444A4 (fr) 1995-08-10 1999-01-13 Merck & Co Inc Pyrroles d'aryle substitues en position 2 et 5, compositions contenant de tels composes et leurs modes d'utilisation
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
CZ292707B6 (cs) 1995-10-06 2003-11-12 Merck & Co., Inc Imidazolové deriváty a farmaceutický prostředek s jejich obsahem
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0859771A4 (fr) 1995-10-31 2000-03-15 Merck & Co Inc Pyrroles de pyridyle substitues, compositions contenant de tels composes et mode d'utilisation
AU7529096A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
AU7482396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Substituted aryl pyrroles, compositions containing such compounds and methods of use
JP3912758B2 (ja) 1996-02-16 2007-05-09 富士フイルム株式会社 １，１−ジ置換−１Ｈ−ベンゾ〔ｅ〕インドール化合物の製造方法及び４〜９位ヒドロキシ基置換の該化合物
EP0889887A4 (fr) 1996-03-25 2003-06-11 Smithkline Beecham Corp Nouveau traitement de lesions du systeme nerveux central
GB0515625D0 (en) 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle

Also Published As

Publication number Publication date
US6602877B1 (en) 2003-08-05
CN1273584A (zh) 2000-11-15
HK1032586A1 (en) 2001-07-27
TWI235751B (en) 2005-07-11
ES2270520T3 (es) 2007-04-01
RU2221795C2 (ru) 2004-01-20
HUP0003309A3 (en) 2002-02-28
IL133311A (en) 2008-11-26
CY1105238T1 (el) 2010-03-03
JP4380803B2 (ja) 2009-12-09
AU742293B2 (en) 2001-12-20
PL337314A1 (en) 2000-08-14
US20040038991A1 (en) 2004-02-26
NO326660B1 (no) 2009-01-26
TR199903098T2 (xx) 2000-07-21
EP0988301B1 (fr) 2006-08-09
SK171099A3 (en) 2001-12-03
CN100443481C (zh) 2008-12-17
ATE335735T1 (de) 2006-09-15
DE69835518D1 (de) 2006-09-21
BR9810007A (pt) 2000-08-15
PT988301E (pt) 2006-10-31
US6989395B2 (en) 2006-01-24
NO996120L (no) 2000-01-24
NO996120D0 (no) 1999-12-10
SK286940B6 (sk) 2009-07-06
HUP0003309A2 (hu) 2002-01-28
KR20010013683A (ko) 2001-02-26
AU7925998A (en) 1998-12-30
PL199893B1 (pl) 2008-11-28
CZ9904452A3 (cs) 2002-02-13
WO1998056788A1 (fr) 1998-12-17
IL133311A0 (en) 2001-04-30
CA2293436A1 (fr) 1998-12-17
EP0988301A1 (fr) 2000-03-29
JP2002503245A (ja) 2002-01-29
CA2293436C (fr) 2010-10-26
DE69835518T2 (de) 2007-08-09
NZ501714A (en) 2001-09-28
BR9810007B1 (pt) 2010-04-06
KR100704059B1 (ko) 2007-04-05

Similar Documents

Publication Publication Date Title
DK0988301T3 (da) Imidazolylcykliske acetaler
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
EA199800391A1 (ru) Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
EA199801047A1 (ru) Замешенные призводные инлазола и их применение в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и фактора некроза опухоли (фно)
ID26620A (id) Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi
ID21529A (id) Metode dan komposisi untuk pengobatan dan pencegahan tumor, gangguan yang berhubungan dengan tumor dan kakeksia
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA199900936A1 (ru) Фунгицидные трифторметилалкиламинотриазолопиримидины
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
DE60011100D1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol-verbindungen
NO20013770L (no) Metoder og blandinger for å öke antall hvite blodceller
MY121548A (en) Compounds and methods for the treatment of cancer
CY1111912T1 (el) Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων
NO982185L (no) Nye makrosykliske forbindelser som metalloproteinaseinhibitorer
EA200201214A1 (ru) Замещенные тиоацетамиды
DK1163208T3 (da) Caspaseinhibitorer og anvendelser deraf
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
EA200200625A1 (ru) Антипикорнавирусные соединения и композиции, их фармацевтическое применение и вещества для их синтеза
DK1051187T3 (da) Behandling af follikulære lymfomer ved anvendelse af inhibitorer af lymfotoxin(LT)-syntesevejen
PT1242410E (pt) Compostos novos
AU7385398A (en) Novel macrocyclic compounds as metalloprotease inhibitors